AL amyloidosis treatment is evolving, bringing new options and new questions for patients. Join us to understand today’s standard treatments and supportive care, emerging approaches such as CAR-T and bispecific therapies, and where autologous stem cell transplant may still fit. Gain a clearer picture of how treatment options are changing and what they may mean for your care.

Raymond L. Comenzo, MD, is a Professor of Medicine and Pathology at Tufts University School of Medicine and a faculty member at Tufts Medical Center. He is an expert in AL amyloidosis. Senior author of the 2021 ANDROMEDA trial, he secured the first FDA-approved therapy for the disease. He also led the 2012 global consensus guidelines for clinical trials and currently directs Tufts' Myeloma and Amyloid Program to advance CAR-T therapies.

AL amyloidosis treatment is evolving, bringing new options and new questions for patients. Join us to understand today’s standard treatments and supportive care, emerging approaches such as CAR-T and bispecific therapies, and where autologous stem cell transplant may still fit. Gain a clearer picture of how treatment options are changing and what they may mean for your care.

Parva Bhatt, MD, MMSc, is Assistant Professor of Medicine and Hematology/Oncology specialist at Tufts Medical Center. Focusing on hematologic malignancies and plasma cell disorders, his clinical work contributes to the diagnosis, risk stratification, and systemic therapy administration for patients presenting with AL amyloidosis and myeloma.

Worries about your health, treatment, and future can sometimes feel overwhelming. Join us to learn practical ways to calm anxious thoughts, cope with uncertainty, and manage fear when it takes over. Gain simple tools to feel more grounded, regain a sense of control, and protect your emotional well-being throughout your care journey.

Akanksha Srivastav, LICSW, is an Oncology Social Worker at Tufts Medical Center specializing in inpatient and outpatient care for hematologic malignancies and AL amyloidosis. Focusing on health equity, she navigates complex psychosocial barriers, facilitates safe care access, and coordinates critical resources across the treatment journey.

A new diagnosis can leave you wondering what to do first and where to turn for help. Join us to learn practical next steps, from understanding your diagnosis and preparing questions to organizing medical information and building the right care team. Gain tools to help you feel more prepared, informed, and confident as you move forward with your care.

Latoya Marshall is the Director of Clinical Research at the Neely Center for Clinical Cancer Research at Tufts Medical Center. With over 17 years of clinical research experience, she leads oncology and hematology research, oversees more than 60 active trials—including five in amyloidosis—and manages partnerships with sponsors and clinical trial networks. She holds an MPH from Boston University and is a Certified Clinical Research Professional.

A new diagnosis can leave you wondering what to do first and where to turn for help. Join us to learn practical next steps, from understanding your diagnosis and preparing questions to organizing medical information and building the right care team. Gain tools to help you feel more prepared, informed, and confident as you move forward with your care.

Jill Marshall, MSN, CCRP, is a Nurse Clinical Research Manager at Tufts Medical Center. Specializing in clinical trial execution and regulatory compliance within the Cancer Center, she oversees site operations for oncology and hematology studies, supporting clinical research protocols for complex plasma cell dyscrasias and AL amyloidosis.

Join a warm welcome to the amyloidosis community and learn the basics of ATTR and AL amyloidosis: what causes each condition, how amyloid can affect different organs, the symptoms, tests, vocabulary, and concepts that matter most, and an overview of available and emerging treatment options. Leave feeling better prepared for care.

Stacey Goodman, MD completed her hematology training at the NIH and Vanderbilt University before joining the faculty in 1993. She helped create and lead the Vanderbilt Amyloidosis Multidisciplinary Program (VAMP) until her retirement in 2021. She currently serves as a member of the board of directors at the Amyloidosis Foundation.

Join a warm welcome to the amyloidosis community and learn the basics of ATTR and AL amyloidosis: what causes each condition, how amyloid can affect different organs, the symptoms, tests, vocabulary, and concepts that matter most, and an overview of available and emerging treatment options. Leave feeling better prepared for care.

David Gusick is the founder of Somebody To Talk To, a program bringing patients, caregivers, and doctors together for free weekly sessions. With 30+ years in systems architecture and entrepreneurship, he is building a global support model to improve quality of life for rare disease patients.

Numbness, tingling, pain, and weakness can have different causes. Join us to learn how AL and ATTR amyloidosis can affect the nerves, how amyloid-related polyneuropathy may differ from nerve compression or entrapment, and how your care team evaluates your symptoms. Gain a clearer understanding of what may be causing your nerve problems and what to discuss with your care team.

Oscar Soto, MD, PhD, is Program Lead for Neuromuscular Disorders at Tufts Medical Center. Dedicated to rare nerve conditions, he specializes in amyloid neuropathy. As Co-PI of the wtATTR-CIAP Burden Study, his research evaluates nerve involvement and disease burden in wild-type ATTR amyloidosis to advance early diagnosis and targeted care.

Numbness, tingling, pain, and weakness can have different causes. Join us to learn how AL and ATTR amyloidosis can affect the nerves, how amyloid-related polyneuropathy may differ from nerve compression or entrapment, and how your care team evaluates your symptoms. Gain a clearer understanding of what may be causing your nerve problems and what to discuss with your care team.

Ron I. Riesenburger, MD, is Chair of Neurosurgery at Tufts University and Tufts Medical Center. A pioneer in spinal amyloidosis research, his work investigates transthyretin (ATTR) amyloid deposition in the ligamentum flavum, linking it to spinal stenosis, carpal tunnel, and early cardiac amyloidosis to advance targeted medical therapies.

Sadness, anger, and fear are natural responses to living with illness, not emotions you need to fix or hide. Join us to explore what these feelings may be telling you and learn simple, research-based tools to move through difficult emotions without feeling overwhelmed. Build resilience while making space for your emotional experience.

Hamide Eygoren, MAPP is a positive psychology expert, educator, and resilience coach dedicated to helping people thrive through life's challenges. Drawing on the science of well-being, resilience, and human flourishing, she teaches practical strategies for finding meaning, cultivating hope, and building emotional strength. Her work empowers individuals facing adversity, including those living with chronic illness, to navigate uncertainty while creating lives of purpose and connection.

Test results can be confusing, especially when you’re unsure what the numbers and medical terms mean for your health. Join us to learn how to review your results, identify important changes, and prepare the right questions for your care team. Gain practical strategies to better understand your results and feel more confident discussing your next steps.

Colin Kloock, MD, is an internal medicine physician and clinical investigator at Tufts Medical Center. Working with the John C. Davis Myeloma and Amyloid Program, his research evaluates trial outcomes like ANDROMEDA, while his clinical practice focuses on early red-flag identification, diagnostic pathways, and systemic amyloidosis management.

Test results can be confusing, especially when you’re unsure what the numbers and medical terms mean for your health. Join us to learn how to review your results, identify important changes, and prepare the right questions for your care team. Gain practical strategies to better understand your results and feel more confident discussing your next steps.

David Drew, MD, is an Associate Professor of Medicine at Tufts University School of Medicine and an attending nephrologist at Tufts Medical Center. His clinical practice centers on general nephrology and chronic kidney disease management, while his research focuses on mineral metabolism, vascular disease, and cognitive function in kidney disease, as well as evaluating renal manifestations in systemic disorders including amyloidosis.

Thanksgiving can bring family, traditions, travel, and special meals, but it can also bring stress, fatigue, and pressure to keep up. Join us to prepare for the holiday by learning how to protect your energy, set boundaries, manage expectations, and stay connected while caring for your health and well-being.

Krystal Griffin, MS CMHC, is a mental health counselor and support group facilitator focused on creating safe, supportive spaces for individuals and families navigating life challenges. She brings a compassionate, community-centered approach to counseling, emotional wellness, and group-based support for the sickle cell community.

Amyloidosis research is moving forward with new studies and potential treatment approaches. Join us to learn about current clinical trials, research underway at Tufts Medicine, and key insights from the Montevideo amyloidosis meeting. Gain a clearer understanding of what researchers are studying and what these advances may mean for the future of care.

Raymond L. Comenzo, MD, is a Professor of Medicine and Pathology at Tufts University School of Medicine and a faculty member at Tufts Medical Center. He is an expert in AL amyloidosis. Senior author of the 2021 ANDROMEDA trial, he secured the first FDA-approved therapy for the disease. He also led the 2012 global consensus guidelines for clinical trials and currently directs Tufts' Myeloma and Amyloid Program to advance CAR-T therapies.

Amyloidosis research is moving forward with new studies and potential treatment approaches. Join us to learn about current clinical trials, research underway at Tufts Medicine, and key insights from the Montevideo amyloidosis meeting. Gain a clearer understanding of what researchers are studying and what these advances may mean for the future of care.

Colin Kloock, MD, is an internal medicine physician and clinical investigator at Tufts Medical Center. Working with the John C. Davis Myeloma and Amyloid Program, his research evaluates trial outcomes like ANDROMEDA, while his clinical practice focuses on early red-flag identification, diagnostic pathways, and systemic amyloidosis management.